Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$10.90M |
$2.44
+1.67%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$10.66M |
$1.33
-4.32%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$10.63M |
$1.53
+1.66%
|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$10.62M |
$0.83
-2.88%
|
|
VASO
Vaso Corporation
Vaso develops and sells medical devices and biometrics-related technology (cardiovascular focus).
|
$10.60M |
$0.17
|
|
CLRB
Cellectar Biosciences, Inc.
Core product category: radiopharmaceuticals developed and marketed by Cellectar as radioconjugate therapies.
|
$10.57M |
$3.17
-4.23%
|
|
MGRX
Mangoceuticals, Inc.
Patented antiviral small-molecule therapeutics (MGX-0024) introduced as an IP asset with clinical development.
|
$10.46M |
$0.82
-17.63%
|
|
CURX
Curanex Pharmaceuticals Inc Common Stock
Lead candidate Phyto-N targets inflammatory diseases, placing CURX in the Biotech - Immunology Therapeutics space.
|
$10.28M |
$0.37
+0.51%
|
|
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
MEDIFLY maggot debridement therapy is Cuprina's flagship wound care device/product.
|
$10.21M |
$0.47
+0.02%
|
|
LFWD
Lifeward Ltd.
LFWD directly designs, manufactures, and sells medical devices (exoskeletons, anti-gravity systems, and rehabilitation solutions), fitting Medical Devices & Biometrics.
|
$10.05M |
$0.62
-2.64%
|
|
QURT
Quarta-Rad, Inc.
Geiger counters and radiation-detection devices are diagnostic/instrumentation equipment, mapping to Diagnostic Equipment.
|
$9.96M |
$0.65
|
|
TRAW
Traws Pharma, Inc.
Company is developing Antiviral Small-Molecule Therapeutics (ratutrelvir) for COVID-19 as a core antiviral program.
|
$9.96M |
$1.41
|
|
YMAT
J-Star Holding Co., Ltd. Ordinary Shares
Offers medical devices & biometrics-related products/services, aligning with healthcare applications.
|
$9.83M |
$0.61
+5.99%
|
|
BIVI
BioVie Inc.
Bezisterim is described as an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, aligning with 'Oral Small Molecule Therapeutics'.
|
$9.79M |
$1.27
-1.92%
|
|
EVGN
Evogene Ltd.
Biomica's microbiome therapeutics program (BMC128) targets human health, fitting Immunology Therapeutics within Biotech.
|
$9.63M |
$1.09
-1.36%
|
|
SINT
Sintx Technologies, Inc.
Core business is manufacturing medical-grade silicon nitride materials used in medical devices, aligning with Medical Devices & Biometrics.
|
$9.63M |
$3.54
+1.43%
|
|
BRTX
BioRestorative Therapies, Inc.
BRTX-100 is an autologous mesenchymal stem cell therapy, the company's lead cell therapy product for disc disease.
|
$9.57M |
$1.21
+0.83%
|
|
LGVN
Longeveron Inc.
LGVN's lead candidate laromestrocel is a mesenchymal stem cell (MSC) therapy, directly aligning with Biotech - Cell Therapy.
|
$9.55M |
$0.63
+0.35%
|
|
CHEK
Check-Cap Ltd.
The company’s legacy C-Scan system is a diagnostic equipment product category (capsule-based CRC screening).
|
$9.42M |
$1.63
+1.24%
|
|
IMNN
Imunon, Inc.
IMUNON's lead candidate IMNN-001 targets ovarian cancer, aligning with Biotech - Oncology.
|
$9.10M |
$4.16
+0.73%
|
|
EPIX
ESSA Pharma Inc.
Directly describes a biotech company focused on oncology drug development (masofaniten) with no revenue; core business is cancer therapeutics.
|
$8.93M |
$0.20
|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$8.92M |
$0.58
+5.12%
|
|
TNON
Tenon Medical, Inc.
Catamaran SI Joint Fusion System and related SI implants are orthopedic devices sold as implants for sacroiliac fusion.
|
$8.88M |
$1.01
+1.50%
|
|
HSCS
HeartSciences Inc.
HeartSciences develops medical devices (wavECG) and biometric sensing capabilities, aligning with Medical Devices & Biometrics.
|
$8.87M |
$3.06
-8.66%
|
|
SEED
Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
|
$8.79M |
$1.14
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$8.58M |
$2.25
-4.47%
|
|
BCDA
BioCardia, Inc.
CardiAMP and CardiALLO are BioCardia's direct cell-therapy programs (autologous and allogeneic) targeted for cardiovascular disease.
|
$8.41M |
$1.46
+0.34%
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Engages in external collaborations/partnerships to provide AI-driven drug development services, akin to CRO-type engagements.
|
$8.38M |
$0.79
-4.90%
|
|
AIMD
Ainos, Inc.
VELDONA human therapeutic programs target rare diseases, aligning with Biotech - Rare Diseases.
|
$8.34M |
$1.81
+1.40%
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$8.25M |
$1.18
+3.07%
|
|
TSBX
Turnstone Biologics Corp.
Company's core business is oncology-focused biotechnology, including immunotherapy approaches (TIL-based strategies) in solid tumors.
|
$8.21M |
$0.35
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$8.15M |
$0.80
-7.99%
|
|
BMRA
Biomerica, Inc.
Biomerica directly manufactures diagnostic tests (inFoods IBS, hpdetect) and related software/equipment.
|
$8.11M |
$2.74
-4.86%
|
|
MRAI
Marpai, Inc.
PBMs (Pharmacy Benefit Managers) theme reflecting MarpaiRx's prescription cost management objectives.
|
$7.52M |
$0.67
|
|
KPRX
Kiora Pharmaceuticals, Inc.
Company's pipeline focuses on ophthalmic therapeutics (KIO-301, KIO-104) targeting retinal degenerative diseases and retinal inflammation, i.e., Ophthalmic Drugs.
|
$7.50M |
$2.19
|
|
BNGO
Bionano Genomics, Inc.
BNGO directly manufactures and sells diagnostic instrument hardware used for Optical Genome Mapping (OGM).
|
$7.35M |
$1.55
-1.27%
|
|
ALZN
Alzamend Neuro, Inc.
ALZN002 is described as a vaccine-based active immunotherapy approach for Alzheimer's.
|
$7.35M |
$2.38
+1.50%
|
Showing page 34 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
